高密度脂蛋白胆固醇与心血管剩余风险  

High-Density Lipoprotein Cholesterol and Residual Cardiovascular Risk

作　　者：苑聪[1,2] 吴洁[1] 

机构地区：[1]南华大学附属第一医院心血管内科,湖南省衡阳市421001 [2]南华大学心血管病研究所动脉硬化学湖南省重点实验室,湖南省衡阳市421001

出　　处：《中国动脉硬化杂志》2012年第11期1045-1050,共6页Chinese Journal of Arteriosclerosis

基　　金：湖南省科技厅重点项目(2009SK2010)

摘　　要：血脂异常是动脉粥样硬化的最主要危险因素之一。从20世纪60年代开始,大量的降低胆固醇临床试验均为"越低越好"的降脂理念奠定了坚固的循证医学基石。他汀类药物可通过降低低密度脂蛋白胆固醇而显著减低心血管事件发生。然而在一些低密度脂蛋白胆固醇已经达标,甚至已降至70 mg/dL以下的患者中,仍然存在着较高的心血管剩余风险。低水平的高密度脂蛋白胆固醇是其最主要的原因之一。因此目前,即使大剂量的强化他汀治疗仍不能完全解决剩余风险的存在。而解决剩余风险的存在对进一步降低心血管病患者的风险又尤为重要。文章主要就高密度脂蛋白胆固醇与心血管剩余风险之间的关系及最新研究进展作进一步归纳和阐述。Dyslipidemia is one of the most important risk factors for atherosclerosis. From the 1960s, a large number of cholesterol-lowering clinical trials had laid a solid cornerstone of evidence-based medicine for the concept ＂the lower the better＂. Statins can significantly reduce the occurrence of cardiovascular events by lowering low-density lipopro- tein cholesterol （LDLC）. However, there is still high residual cardiovascular risk in some patients who have achieved lower levels of LDLC, even when LDLC 〈 70 mg/dL. High doses of intensive statin therapy can not completely solve the remnants of the residual risk. It is of great importance to solve the residual risk so as to further reduce the rates of cardio- vascular events. This article aims to review the latest advances to clarify the relationship between high-density lipoprotein cholesterol （HDLC） and residual cardiovascular risk.

关 键 词：血脂异常 高密度脂蛋白胆固醇 冠心病 他汀 心血管剩余风险 

分 类 号：R5[医药卫生—内科学]